HAE stock news · Haemonetics Corporation
Get alerts for HAE
Follow Haemonetics Corporation (HAE) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for HAEHaemonetics shares reach their highest price in a year after a big deal with CSL Plasma.
Good for HAEHaemonetics may supply devices and disposable products across CSL Plasma’s U.S. centers. This could bring repeat sales, making the news positive, but the rollout and sales impact are not settled.
Haemonetics shares reach their highest price in a year after CSL Plasma plans to use its devices nationwide.
Good for HAEHaemonetics could sell more collection devices and disposable products as CSL plans a broader rollout. The plan remains unfinished, but it points to more demand.
On Thursday, 12 health care stocks saw big changes in their prices during the day.
NeutralHaemonetics shares rose 18% during Thursday's session, but the article reports no company news. The share move alone does not change its business outlook.
12 health care stocks are changing a lot before the market opens on Thursday.
NeutralThe roundup reports Haemonetics shares rose 19.94% before the market opened. It gives no company news to show a change in the business outlook.
Haemonetics shares details from its first-quarter earnings call for 2027.
Good for HAEHaemonetics’ first-quarter sales rose 6%, and adjusted profit per share rose 4%. It also lifted its FY2027 sales outlook, making this update positive despite slower cell-salvage upgrades.
New 52-week peak reached by Haemonetics shares: What’s driving the surge?
NeutralHaemonetics shares surged to a new 52-week high following the announcement of a significant supply agreement with CSL Plasma, which will allow CSL to utilize Haemonetics' advanced devices across its U.S. network. This development is expected to positively impact Haemonetics' market position, although the company has not adjusted its fiscal guidance yet.
HAEMONETICS CORP: Financial Performance and Operational Results Disclosed (HAE).
NeutralHaemonetics Corp has filed a Form 8-K detailing its results of operations and financial condition, which is crucial for investors assessing the company's performance. The immediate nature of this filing suggests potential volatility in the stock as investors react to the new information.